DFMO acts in a multifaceted way to enhance the cytotoxic effects of PARP inhibitors, suggesting that it may be a useful adjunct chemotherapeutic approach to improve the anti-tumor efficacy of PARP inhibitors in treating ovarian cancer. Here, PARP1 is linked to neoplasm.